Rafferty Asset Management LLC Sells 11,014 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Rafferty Asset Management LLC decreased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 17.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,817 shares of the biopharmaceutical company's stock after selling 11,014 shares during the period. Rafferty Asset Management LLC's holdings in Alnylam Pharmaceuticals were worth $12,428,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of ALNY. Regeneron Pharmaceuticals Inc. bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $1,045,822,000. Norges Bank bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $577,941,000. Capital Research Global Investors grew its holdings in shares of Alnylam Pharmaceuticals by 32.9% in the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after acquiring an additional 1,724,610 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 39.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock valued at $1,031,705,000 after acquiring an additional 1,245,195 shares in the last quarter. Finally, Marshall Wace LLP grew its holdings in shares of Alnylam Pharmaceuticals by 496.6% in the 4th quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company's stock valued at $89,100,000 after acquiring an additional 315,182 shares in the last quarter. Institutional investors own 92.97% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Bank of America raised their target price on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a research note on Friday, March 21st. Chardan Capital raised their target price on shares of Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Stifel Nicolaus raised their target price on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research note on Monday, March 31st. StockNews.com upgraded shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, HC Wainwright reiterated a "buy" rating and issued a $500.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. One analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $319.17.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY traded down $0.18 during midday trading on Tuesday, reaching $291.68. The company's stock had a trading volume of 627,258 shares, compared to its average volume of 913,005. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $146.79 and a fifty-two week high of $304.39. The business's 50 day moving average price is $254.72 and its two-hundred day moving average price is $253.61. The company has a market cap of $38.03 billion, a P/E ratio of -134.41 and a beta of 0.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The firm had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. The company's quarterly revenue was up 20.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.16) EPS. On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.